29,314 Definium Therapeutics, Inc. $DFTX Shares Bought by Profund Advisors LLC

Profund Advisors LLC grew its holdings in Definium Therapeutics, Inc. (NASDAQ:DFTX) by 216.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 42,885 shares of the company’s stock after buying an additional 29,314 shares during the period. Profund Advisors LLC’s holdings in Definium Therapeutics were worth $1,632,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wellington Management Group LLP bought a new position in shares of Definium Therapeutics in the 2nd quarter valued at about $138,755,000. Bank of New York Mellon Corp grew its position in Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after acquiring an additional 24,349 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in Definium Therapeutics in the second quarter worth about $6,992,000. Moody Aldrich Partners LLC grew its position in Definium Therapeutics by 191.8% in the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after acquiring an additional 97,845 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in Definium Therapeutics by 2.6% during the third quarter. Nisa Investment Advisors LLC now owns 49,607 shares of the company’s stock worth $1,888,000 after acquiring an additional 1,238 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Brandi Roberts sold 3,377 shares of the business’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the completion of the transaction, the chief financial officer owned 394,528 shares in the company, valued at $14,427,888.96. The trade was a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew T. Wiley sold 3,097 shares of the business’s stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $113,257.29. Following the transaction, the insider owned 359,036 shares of the company’s stock, valued at approximately $13,129,946.52. The trade was a 0.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,098 shares of company stock worth $2,626,115. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DFTX. Canaccord Genuity Group set a $78.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. Bank of America started coverage on Definium Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, October 15th. Needham & Company LLC reissued a “buy” rating and set a $66.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, JonesTrading increased their price target on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $66.00.

Definium Therapeutics Stock Performance

Shares of NASDAQ:DFTX opened at $32.47 on Tuesday. The company has a market capitalization of $4.36 billion, a price-to-earnings ratio of -9.47 and a beta of 2.19. Definium Therapeutics, Inc. has a 12 month low of $10.46 and a 12 month high of $49.70. The firm’s 50-day moving average is $37.52 and its 200 day moving average is $29.60. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts predict that Definium Therapeutics, Inc. will post -3.08 EPS for the current year.

Definium Therapeutics Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.